Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans
- 1 March 1999
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 276 (3) , G655-G665
- https://doi.org/10.1152/ajpgi.1999.276.3.g655
Abstract
Epithelial cells lining the adult human colon do not normally express gastrin-releasing peptide (GRP) or its receptor (GRPR). In contrast, approximately one-third of human colon cancers and cancer cell lines have been shown to express GRP-binding sites. Because GRPR activation causes the proliferation of many cancer cell lines, GRP has been presumed to act as a clinically significant growth factor. Yet GRP has not been shown to be expressed by colon cancers in humans nor has the effect of GRP and/or GRPR coexpression on tumor behavior been investigated. We therefore determined GRP and GRPR expression by immunohistochemistry in 50 randomly selected colon cancers resected between 1980 and 1997, all 37 associated lymph node and liver metastases, and 20 polyps. Tumor sections studied were those that contained the margin and adjacent nonmalignant epithelium. Overall, 84% of cancers aberrantly expressed GRP or GRPR, with 62% expressing both ligand and receptor, whereas expression was not observed in adjacent normal epithelium. Consistent with the previously established mitogenic capabilities of GRP, tissues coexpressing GRP and GRPR were more likely to express proliferating cell nuclear antigen than tissues not expressing both ligand and receptor. Yet GRP/GRPR coexpression was seen with equal frequency in stage A as in stage D cancers and was only detected in 1 in 37 metastases. Furthermore, Kaplan-Meier analysis did not reveal any difference in patient survival between those whose tumors did or did not express GRP/GRPR. In contrast, GRP/GRPR coexpression was found in all well-differentiated tumor regions, whereas poorly differentiated tissues never coexpressed GRP/GRPR. Overall, these data indicate that, although GRP is a mitogen, it is not a clinically significant growth factor in human colon cancers. Rather, the strong association of GRP/GRPR coexpression with tumor differentiation raises the possibility that these proteins primarily act in vivo as morphogens.Keywords
This publication has 30 references indexed in Scilit:
- Constitutive activation of the gastrin-releasing peptide receptor expressed by the nonmalignant human colon epithelial cell line NCM460.Journal of Clinical Investigation, 1997
- Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude miceInternational Journal of Cancer, 1993
- Bombesin Receptor Gene Expression in Rat Embryos: Transient GRP-R Gene Expression in the Posterior PituitaryMolecular and Cellular Neuroscience, 1993
- Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factorPublished by Elsevier ,1991
- The receptor encoded by the human C‐MET oncogene is expressed in hepatocytes, epithelial cells and solid tumorsInternational Journal of Cancer, 1991
- Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene ProductScience, 1991
- Characterization, in some human breast cancer cell lines, of gastrin‐releasing peptide‐like receptors which are absent in normal breast epithelial cellsInternational Journal of Cancer, 1990
- CADHERINS: A MOLECULAR FAMILY IMPORTANT IN SELECTIVE CELL-CELL ADHESIONAnnual Review of Biochemistry, 1990
- Localization of Bombesin Receptors in the Human Gastrointestinal Tract Using Quantitative Receptor AutoradiographyAnnals of the New York Academy of Sciences, 1988
- I. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancerLife Sciences, 1985